Delivery Order SPE2DB20D1109-SPE2DB22FQ13X
- Not listed
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is for the delivery of Dupixent 200 mg/1.14 ml syringes. The $52,992.43 firm fixed-price delivery order was placed by the Defense Logistics Agency (DLA) Troop Support Medical. The contract has an ultimate completion date of February 8, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the...
- This federal contract award to Amerisourcebergen Drug Corp, a division of parent company Cencora, Inc., is a Delivery Order valued at $49,738.83 for the supply of Dupixent 300 mg/2 ml syringes. The contract was awarded by the Defense Logistics Agency (DLA) Troop Support Medical, a component of the Department of Defense (DoD). Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026, which...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $9,159.47 for the pharmaceutical product Dupixent 200 mg/1.14 ml syringe. The award was made by the Defense Logistics Agency (DLA), a defense agency, and does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that serves as the primary vehicle...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is for the delivery of Dupixent 300 mg/2 ml syringe (2 ml) to the Defense Logistics Agency (DLA) Troop Support Medical. The $25,934.80 firm-fixed-price delivery order has an ultimate completion date of October 3, 2023. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company to provide a...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $8,371.10 for the pharmaceutical product Dupixent 300 mg/2 ml syringe. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves...
- This federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is for the delivery of Dupixent 300 mg/2 ml syringes. The $4,957.08 fixed-price delivery order has an ultimate completion date of April 12, 2023. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for providing a comprehensive range of pharmaceutical products...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $21,423.80 for the pharmaceutical product Dupixent 200 mg/1.14 ml syringe. The award was made by the Defense Logistics Agency (DLA), a defense agency, and does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $1,917.67 for the pharmaceutical product Dupixent 300 mg/2 ml syringe. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of January 30, 2024. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $33,027.32 firm-fixed-price delivery order is for the pharmaceutical product Dupixent 300 mg/2 ml syringe. The ultimate completion date for this contract is March 7, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order awarded by the Defense Logistics Agency (DLA) for the supply of Dupixent 300 mg/2 ml syringes. The award, valued at $6,530.09, is a firm-fixed-price contract with a completion date of February 27, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB22FQ13XDelivery Order
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $26,542.08 for the supply of Dupixent 200 mg/1.14 ml syringes. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has no set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract encompasses critical medical commodities including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains. In addition, Amerisourcebergen maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $26.5k | 9/21/22 |